Chia‐Chi Lin

Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1–2 trial

Alice T. Shaw, Benjamin Solomon, Rita Chiari et al. · The Lancet Oncology · 2019 · 352 citations

Medicine, Oncology, Pharmacology +11

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non–Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis

Bin-Chi Liao, Jih‐Hsiang Lee, Chia‐Chi Lin et al. · Journal of Thoracic Oncology · 2015 · 195 citations · Full text

Medicine, Oncology, Pharmacology +12

Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study

Chia‐Chi Lin, Jin‐Yuan Shih, Chong‐Jen Yu et al. · The Lancet Respiratory Medicine · 2017 · 144 citations

Medicine, Genetics, Oncology +16

Arsenic trioxide in patients with hepatocellular carcinoma: a phase II trial

Chia‐Chi Lin, Chiun Hsu, Chih‐Hung Hsu et al. · Investigational New Drugs · 2006 · 123 citations

Medicine, Oncology, Toxicology +15

Moving Beyond 3+3: The Future of Clinical Trial Design

Razelle Kurzrock, Chia‐Chi Lin, Tsung‐Che Wu et al. · American Society of Clinical Oncology Educational Book · 2021 · 107 citations · Full text

Medicine, Oncology, Pharmacology +15